Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1189 EBV Vaccine in Healthy Adolescents and Adults
NCT05164094Phase 2Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Dec 2021
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-1189 in Epstein-Barr virus infection, sponsored by Moderna Inc. Started Dec 2021; status: active, not recruiting.
02
Drugs
mRNA-1189
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT05164094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164094.